Difference between revisions of "Apatinib (Aitan)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Chemotherapeutic" to "") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Kinase inhibitors" to "") |
||
Line 15: | Line 15: | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
− | + | ||
[[Category:VEGFR inhibitors]] | [[Category:VEGFR inhibitors]] | ||
[[Category:KIT inhibitors]] | [[Category:KIT inhibitors]] |
Revision as of 23:07, 28 February 2020
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Apatinib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.
Diseases for which it is used
Also known as
- Code name: YN968D1
- Generic name: rivoceranib
- Brand name: Aitan